Literature DB >> 9585153

The use of irreversible ligands to inactivate receptor subtypes: 4-DAMP mustard and muscarinic receptors in smooth muscle.

F J Ehlert1, M T Griffin.   

Abstract

Irreversible ligands are useful tools for investigating the function of receptor subtypes in various physiological processes. The mechanism for alkylation involves the formation of a reversible receptor complex followed by a covalent reaction. The extent of receptor alkylation is determined by the dissociation constant of the reversible complex and the rate constant for conversion to the covalent complex. Selectivity can be achieved if the irreversible ligand exhibits a difference in its dissociation constants for receptor subtypes. Selective alkylation can also be achieved using a selective competitive inhibitor to protect the desired receptor subtype. By using the non-M2-selective irreversible antagonist, 4-DAMP mustard, in combination with the competitive M2-selective antagonist, AF-DX 116, it has been possible to achieve a highly selective inactivation of all non-M2 subtypes of the muscarinic receptors in smooth muscle and has enabled the discovery of the functional role of M2 receptors in smooth muscle.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9585153     DOI: 10.1016/s0024-3205(98)00124-6

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  2 in total

1.  Pilocarpine modulates the cellular electrical properties of mammalian hearts by activating a cardiac M3 receptor and a K+ current.

Authors:  H Wang; H Shi; Y Lu; B Yang; Z Wang
Journal:  Br J Pharmacol       Date:  1999-04       Impact factor: 8.739

2.  Muscarinic receptor subtypes involved in carbachol-induced contraction of mouse uterine smooth muscle.

Authors:  Takio Kitazawa; Ryuichi Hirama; Kozue Masunaga; Tatsuro Nakamura; Koichi Asakawa; Jinshan Cao; Hiroki Teraoka; Toshihiro Unno; Sei-ichi Komori; Masahisa Yamada; Jürgen Wess; Tetsuro Taneike
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-12-11       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.